Please login to the form below

Ashfield publishes white paper on sales outsourcing as a change partner

Ashfield, assisted by Dr Beth Rogers, has investigated the future of outsourcing with 16 senior sales and buying professionals from pharmaceutical companies across Europe. The insights are shared in our whitepaper, ‘Flex in a time of flux: Sales outsourcing as a change partner in the pharmaceutical sector.’

Pharmaceutical companies are facing unprecedented change. Product portfolios are migrating from mass market solutions to highly specialised therapies, relevant to relatively small patient populations. Reimbursement is becoming increasingly complex and successful commercialisation means targeting multiple stakeholders before a prescription is even written.

In response, the pharma industry is exploring new sales and marketing models, evolving its core strategies to meet these modern, multifaceted challenges.

Historically, contract sales organisations (CSOs) have provided a flexible, cost-effective means for the pharma industry to adjust the implementation of its sales strategy. However, given the current state of flux, just how relevant can CSOs be in helping pharma manage such major change?

In July 2017, Ashfield conducted an online Advisory Board discussion to investigate the issue. The participants included 14 senior sales and buying professionals from pharmaceutical companies across Europe. Together, they debated the advantages, challenges and possible future use of CSOs. Five follow-up interviews – including two with additional clients – and an Ashfield idea generation session were also undertaken.

Dr Beth Rogers, author of Rethinking Sales Management and several articles and papers on the outsourcing of sales functions, assisted Ashfield in moderating the advisory board, conducting the follow-up interviews and writing the white paper.

This white paper considers how the relationship between pharmaceutical companies and CSOs has developed and the characteristics that pharmaceutical companies today look for in a strategic CSO partner. It also explores how that relationship is expected to change in the next five years, and how services and outsourcing models will evolve.

Click here to download the white paper!

2nd November 2017



Company Details


Contact Website

Ashfield House
Resolution Road
Ashby de la Zouch
LE65 1HW

Latest content on this profile

Ashfield wins Best Newcomer at the Pf Awards 2018
We are thrilled to announce that Zuchaela Smylie, from Ashfield, won Best Newcomer at the 2018 Pf Awards, the largest pharmaceutical sales awards in the UK. The awards ceremony took place on Thursday, 9 March at The Lancaster Hotel in London.
“It is evident that meeting face-to-face is still highly valued in the digital age”
Attending a scientific congress or meeting overtakes professional journals and publications as the educational channel of choice for Healthcare Professionals – according to findings of new study
Ashfield to present at the Orphan Drugs for Rare Diseases Summit
Ashfield has a breadth of experience with orphan drugs and we are passionate about helping to improve the lives of people living with rare diseases. We are delighted to be sponsoring and presenting at the ‘Orphan Drugs for Rare Diseases’ event 22-23 March in Berlin.
Addressing the biggest challenges for rare disease communities
Each year, Rare Disease Day takes place worldwide on the last day in February. The main objective of Rare Disease Day is to raise awareness amongst the general public, the healthcare industry and decision-makers about rare diseases and their impact on patients' lives.
Humanise is our strategic approach to healthcare communications. It’s based on the need to understand. It looks at the emotions that make us human. It examines the feelings we have as individuals. It defines the behaviours we show as people.
Ashfield launches new commercial model to improve ROI
Ashfield, part of UDG Healthcare, a global leader in providing outsourced healthcare services, has announced the launch of a pioneering new commercial model called The Ashfield Solution.